Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Prolonged Lymphopenia and Infection Risk Is Mitigated By Antimicrobial Prophylaxis in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Treated with Bendamustine +/- Anti-CD20 Antibody: The Australasian Lymphoma Alliance Experience

Kate Manos, MBBS, Masa Lasica, MD, Andrew Grigg, MBBS, MD FRACP, FRCPA, Pietro R Di Ciaccio, BA/LLB MBBS FRACP FRCPA, Jonathan Wong, MBBS, Usha Chandra Sekaran, Joel Wight, Zhong Goh, Hayden Jina, Llewyn Butler, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA, Gareth P. Gregory, Shane A Gangatharan, MBBS, FRACP, FRCPA, Tara Cochrane, MBBS,FRCPA,FRACP, Kristen Piper, Leonid Churilov, Eliza A Hawkes, FRACP,MDMBBS

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-138642

Published: 2020

Journal Articles

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Blood (2020) 136 (Supplement 1): 36–38.

https://doi.org/10.1182/blood-2020-137334

Published: 2020

Journal Articles

Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study

Eliza A Hawkes, FRACP,MDMBBS, Geoffrey Chong, MD, Charmaine Smith, Sze-Ting Lee, Leonid Churilov, Joseph McKendrick, William Renwick, Piers Blombery, MBBS, Niles Elizabeth Nelson, BSc, MBBS, Tineke Fancourt, Joanne Hawking, Wendi Lin, Andrew M Scott, Allison Barraclough, Joel Wight, Andrew Grigg, MBBS, MD FRACP, FRCPA, Colm Keane, MD, Chun Yew Fong, MBBS, PhD FRACP, FRCPA, Kate Manos, MBBS

Blood (2020) 136 (Supplement 1): 43–44.

https://doi.org/10.1182/blood-2020-136024

Published: 2020

Journal Articles

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Natasha S Anstee, PhD, Giovanna Pomilio, Mark Levis, MD PhD, Sarah MacRaild, Michael Murray, PhD DSc, Tristan Rawling, PhD, Glen A Kennedy, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Anthony Schwarer, MBBS, MD FRACP, FRCPA, Anoop Kumar Enjeti, MBBS,FRCPA, FRACP, PhD MD MRCP, James D'Rozario, MBBS, FRACP, FRCPA, Paula Marlton, MBBS FRACP FRCPA, Ian Bilmon, BMBS, FRACP, FRCPA, Adam Ivey, BSc, MSc, PhD, Doen Ming Ong, MBBS, Andrew W Roberts, MBBS, Andrew H Wei, MBBS, PhD

Blood (2020) 136 (Supplement 1): 16–18.

https://doi.org/10.1182/blood-2020-141711

Published: 2020

Journal Articles

Evaluation of a Safe Neutrophil Count for Cessation of IV Antibiotics and Early Hospital Discharge in Stable, Afebrile Patients Recovering after Acute Myeloid Leukaemia (AML) Therapy or an Autograft

Chih-Chiang Hu, Rakhee Subramanian, MBBS, Andrew Grigg, MBBS, MD FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-137284

Published: 2020

Journal Articles

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Blood (2017) 130 (Supplement 1): 2898.

https://doi.org/10.1182/blood.V130.Suppl_1.2898.2898

Published: 2017

Journal Articles

Efficacy and Safety of Subcutaneous or Intravenous Administration of Rituximab in Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Final Results of the Randomized, Open-Label, Crossover, PrefMab Study

Mathias J Rummel, Tae Min Kim, Franco Aversa, MD, Wolfram Brugger, MDPhD, Enrico Capochiani, Caterina Plenteda, Francesca Re, Peter Task, Christine McIntyre, Oliver Meier, Stuart Osborne, Rodney Smith, Andrew Grigg, MBBS FRACP FRCPA

Blood (2017) 130 (Supplement 1): 2834.

https://doi.org/10.1182/blood.V130.Suppl_1.2834.2834

Published: 2017

Journal Articles

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Bradstock Kenneth, Emma Link, DPhil, Juliana Di Iulio, BAppSc, PhD, Jeff Szer, MB, BS, FRACP, Paula Marlton, MBBS, FRCPA, FRACP, Andrew Wei, MBBS, PhD, Arno Enno, MB,BS,FRCPA, FRACP, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Ian D. Lewis, MBBS PhDFRACP FRCPA, James D'Rozario, MB BS FRACP, Luke Coyle, MBBS, FRACP, FRCPA, Gavin Cull, MBBS DM FRACP FRCPA, Philip Campbell, MB ChB FRACP FRCPA, Michael Francis Leahy, FRACP, Uwe H Hahn, MDFGCP FRCPA, Paul Cannell, MD, Campbell Tiley, MBBS,FRACP, FRCPA, Raymond M. Lowenthal, MD FRACP, FRCP, John Moore, MBBS, MD FRACP , FRCPA, Kimberly Cartwright, FRACP,MDFRCPA, Ilona Cunningham, John Taper, MBBS FRACP FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Andrew W. Roberts, MBBS PhD, Warwick John Benson, Mark S Hertzberg, MBBS PhDFRACP FRCPA, Sandra F. Deveridge, MDBSc,FRACP,FRCPA, Philip Arthur Rowlings, FRACP,FRCPA,MBBS,MS, Anthony K. Mills, MBBS, FRACP, FRCPA, Devinder S Gill, MBChB FRCPath MRCP, Peter G Bardy, MBBS, FRACP, FRCPA, Lynda Campbell, John F. Seymour, MD

Blood (2016) 128 (22): 338.

https://doi.org/10.1182/blood.V128.22.338.338

Published: 2016

Journal Articles

Limited Utility of Routine Chest X-Ray (CXR) in Initial Evaluation of Febrile Neutropenia in Patients with Haematological Diseases Undergoing Chemotherapy

Ortis Estacio, Zoe Loh, Andrew Grigg, MBBS, MD FRACP, FRCPA, Amy Baker, Leonid Churilov, Geoff Chong, MD, Eliza A Hawkes

Blood (2016) 128 (22): 3549.

https://doi.org/10.1182/blood.V128.22.3549.3549

Published: 2016

Journal Articles

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

Blood (2016) 128 (22): 939.

https://doi.org/10.1182/blood.V128.22.939.939

Published: 2016

Journal Articles

High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?

Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Joel Wight, MBBS, Kathryn Jackson, MBBS, Ashanka Mahilal Beligaswatte, BA, MBBS, MD FRACP, FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Glen Kennedy, MBBS, FRACP, FRCPA, Louisa Martin, MBBS, Ian D. Lewis, MBBS PhD FRACP FRCPA, Devendra Hiwase, MBBS, FRACP, FRCPA, MD PhD, Daniela Zantomio, FRACP, FRCPA, MBBS, Simon Z. He, MBBS,FRACP,FRCPA, Andrew Grigg, MBBS, MD FRACP, FRCPA, Kirk Morris, FRACP FRCPA MBBS, Peter Mollee, MBBS, MMedSc, FRACP, FRCPA, Paula Marlton, MBBS

Blood (2016) 128 (22): 3989.

https://doi.org/10.1182/blood.V128.22.3989.3989

Published: 2016

Journal Articles

A Multicentre Study Investigating the Pharmacokinetics and Pharmacodynamics of Busulphan When Combined with Melphalan As Conditioning in Adult Autologous Transplant Recipients

Abbey Willcox, MBBS, Eric Wong, Ashish R Bajel, MBBS, FRACP, FRCPA, Simon J. Harrison, Rosemary Thurston Hoyt, RN, BSN, Brett Janson, Christa Nath, BSC (Hons), PhD, Peter J Shaw, David Ritchie, MD PhD, Andrew Grigg, MBBS, MD FRACP, FRCPA

Blood (2016) 128 (22): 2190.

https://doi.org/10.1182/blood.V128.22.2190.2190

Published: 2016

Journal Articles

Patient Selection for High-Dose Methotrexate As Central Nervous System Prophylaxis in Diffuse Large B-Cell Lymphoma in Australia: Are We Getting It Right?

Melissa Garwood, Eliza A Hawkes, Leonid Churilov, Andrew Grigg, MBBS, MD FRACP, FRCPA, Geoff Chong, MD

Blood (2016) 128 (22): 4217.

https://doi.org/10.1182/blood.V128.22.4217.4217

Published: 2016

Journal Articles

Prognostic Markers in Core-Binding Factor Acute Myeloid Leukaemia

Ashvind A Prabahran, MBBS, Mark Tacey, BSc, Shaun Fleming, MBBS (Hons), FRACP, FRCPA, Danielle Strong, Andrew Wei, MBBS, PhD, Courtney Tate, MBBS, Paula Marlton, MBBS, Joel Wight, MBBS, Andrew Grigg, MBBS, MD FRACP, FRACPA, Annabel Tuckfield, MBBS, FRACP, FRCPA, PhD, Jeff Szer, MB, BS, FRACP, David S. Ritchie, MDPhD, Lynette C.Y. Chee, MBBS, FRACP, FRCPA, PhD

Blood (2015) 126 (23): 2599.

https://doi.org/10.1182/blood.V126.23.2599.2599

Published: 2015

Journal Articles

Prefmab: Final Analysis of Patient Preference for Subcutaneous Versus Intravenous Rituximab in Previously Untreated CD20+ Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

Mathias Rummel, MD PhD, Tae Min Kim, MD PhD, Caterina Plenteda, MD, Enrico Capochiani, MD, Maria Mendoza, Rodney Smith, MD PhD, Stuart Osborne, MSc, Andrew Grigg, MBBS, MD FRACP, FRACPA

Blood (2015) 126 (23): 3972.

https://doi.org/10.1182/blood.V126.23.3972.3972

Published: 2015

Journal Articles

High Dose Cytarabine (HiDAC) and Fludarabine Without Anthracycline For Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): The Australasian Leukaemia and Lymphoma Group (ALLG) AMLM13 Study

Paula Marlton, MBBS, John F Seymour, MBBS, PhD, Kenneth Bradstock, MBBS, PhD, Ian D Lewis, MB, BS, PhD, Russell Saal, BAppSci, MMedSci, Lyle McMillen, BSc, PhD, Juliana Di Iulio, BAppSc, PhD, Diana Zannino, BSc, MSc, Andrew Grigg, MBBS

Blood (2013) 122 (21): 1444.

https://doi.org/10.1182/blood.V122.21.1444.1444

Published: 2013

Journal Articles

Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis

Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, David T Yeung, BSc, MBBS, FRACP, FRCPA, Lisa Carne, RN, David Ross, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS

Blood (2013) 122 (21): 1503.

https://doi.org/10.1182/blood.V122.21.1503.1503

Published: 2013

Journal Articles

Autologous Hematopoietic Cell Transplantation (HCT) Is Superior To Allogeneic Transplantation For Acute Promyelocytic Leukemia In Second Complete Remission (CR2)

Jennifer L. Holter-Chakrabarty, MD, Morel Rubinger, MD, Andrew Grigg, MBBS, FRACP, FRCPA, Jeffrey Szer, MBBS, George Selby, MD, Jacob M Rowe, MD, Jennifer Le Rademacher, PhD, Hailin Wang, MS, Daniel J. Weisdorf, MD, Martin S Tallman, MD

Blood (2013) 122 (21): 418.

https://doi.org/10.1182/blood.V122.21.418.418

Published: 2013

Journal Articles

Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)

Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Andrew Grigg, MBBS, FRACP, FRCPA, Marcos González, Martin Dreyling, Simon A. Rule, MD, Guiyuan Lei, Elisabeth Wassner-Fritsch, Michael K. Wenger, MD, Paula Marlton, MBBS, FRACP, FRCPA

Blood (2012) 120 (21): 3686.

https://doi.org/10.1182/blood.V120.21.3686.3686

Published: 2012

Journal Articles

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

David T Yeung, BSc, MBBS, FRACP, FRCPA, Michael Philip Osborn, MBBS, Deborah L White, PhD, Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, MBChB, FRACP, FRCPA, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, on Behalf Of ALLG

Blood (2012) 120 (21): 3771.

https://doi.org/10.1182/blood.V120.21.3771.3771

Published: 2012

NARROW

Prolonged Lymphopenia and Infection Risk Is Mitigated By Antimicrobial Prophylaxis in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Treated with Bendamustine +/- Anti-CD20 Antibody: The Australasian Lymphoma Alliance Experience

Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)

Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study

The Impact of Sorafenib on Phospho-FLT3 Inhibition and FLT3 -ITD MRD after Chemotherapy: Correlative Studies from the Phase 2 Randomized Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3 -ITD Acute Myeloid Leukemia (ALLG AMLM16)

Evaluation of a Safe Neutrophil Count for Cessation of IV Antibiotics and Early Hospital Discharge in Stable, Afebrile Patients Recovering after Acute Myeloid Leukaemia (AML) Therapy or an Autograft

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Efficacy and Safety of Subcutaneous or Intravenous Administration of Rituximab in Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Final Results of the Randomized, Open-Label, Crossover, PrefMab Study

Increased Idarubicin Dosage during Consolidation Therapy for Adult Acute Myeloid Leukemia Improves Leukemia-Free Survival

Limited Utility of Routine Chest X-Ray (CXR) in Initial Evaluation of Febrile Neutropenia in Patients with Haematological Diseases Undergoing Chemotherapy

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

High-Dose Cytarabine (HiDAC) Improves the Cure Rate of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Is It Better to be Given As Induction Therapy or As Consolidation Therapy?

A Multicentre Study Investigating the Pharmacokinetics and Pharmacodynamics of Busulphan When Combined with Melphalan As Conditioning in Adult Autologous Transplant Recipients

Patient Selection for High-Dose Methotrexate As Central Nervous System Prophylaxis in Diffuse Large B-Cell Lymphoma in Australia: Are We Getting It Right?

Prognostic Markers in Core-Binding Factor Acute Myeloid Leukaemia

Prefmab: Final Analysis of Patient Preference for Subcutaneous Versus Intravenous Rituximab in Previously Untreated CD20+ Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

High Dose Cytarabine (HiDAC) and Fludarabine Without Anthracycline For Patients With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): The Australasian Leukaemia and Lymphoma Group (ALLG) AMLM13 Study

Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis

Autologous Hematopoietic Cell Transplantation (HCT) Is Superior To Allogeneic Transplantation For Acute Promyelocytic Leukemia In Second Complete Remission (CR2)

Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only